Depth and Rapidity of Response With Abrocitinib and Dupilumab in Patients With Moderate-to-Severe Atopic Dermatitis (AD) in JADE COMPARE

Abstract

Emerging treatments for moderate-to-severe AD could provide greater and faster improvement in AD signs and symptoms than current therapies. A post hoc analysis of stringent endpoints with abrocitinib and dupilumab was conducted using JADE COMPARE (NCT03720470) data.